Roth Capital Has Pessimistic View of ChromaDex Q2 Earnings

ChromaDex Co. (NASDAQ:CDXC) – Analysts at Roth Capital cut their Q2 2025 EPS estimates for shares of ChromaDex in a research report issued on Friday, November 1st. Roth Capital analyst S. Mcgowan now forecasts that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.01. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for ChromaDex’s Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.01 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.03 EPS and FY2026 earnings at $0.08 EPS.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 5.06% and a net margin of 1.62%. During the same period in the prior year, the business earned ($0.01) EPS.

Separately, HC Wainwright upped their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday.

ChromaDex Stock Performance

CDXC stock opened at $5.74 on Monday. The firm has a 50-day simple moving average of $3.57 and a two-hundred day simple moving average of $3.24. ChromaDex has a one year low of $1.32 and a one year high of $6.18. The firm has a market cap of $435.84 million, a price-to-earnings ratio of 574.57 and a beta of 1.88.

Insider Buying and Selling

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 9.64% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ChromaDex

Several institutional investors and hedge funds have recently modified their holdings of the business. Miracle Mile Advisors LLC purchased a new stake in ChromaDex in the 2nd quarter worth $27,000. The Manufacturers Life Insurance Company purchased a new position in ChromaDex in the 2nd quarter valued at about $31,000. Merriman Wealth Management LLC acquired a new stake in ChromaDex in the 2nd quarter worth about $32,000. Lazard Asset Management LLC purchased a new stake in ChromaDex during the 1st quarter worth approximately $43,000. Finally, SG Americas Securities LLC acquired a new position in shares of ChromaDex during the first quarter valued at approximately $54,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.